ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer

Zhang, Jiexia; Zhou, Ningning; Lin, Anqi; Luo, Peng; Chen, Xin; Deng, Huojin; Kang, Shijun; Guo, Linlang*; Zhu, Weiliang*; Zhang, Jian南方医科大学; 中山大学
Cancer Immunology, Immunotherapy2021-1DOI: 10.1007/s00262-020-02668-8
60被引5阅读
引用收藏
分享

摘要

To date, immunotherapy has opened a new chapter in the treatment of lung cancer. Precise biomarkers can help to screen subpopulations of lung cancer to provide the best treatment. Multiple studies suggest that specific gene mutations may be predictive markers in guiding non-small cell lung cancer (NSCLC) immune checkpoint inhibitor (ICI) treatment. A published immunotherapy cohort with mutational and survival data for 350 NSCLC patients was used. First, the mutational data of the immunotherapy cohort were used to identify gene mutations related to the prognosis of ICI therapy. The immunotherapy cohort and TCGA-NSCLC cohort were further studied to elucidate the relationships between specific gene mutations and tumor immunogenicity, antitumor immune response capabilities, and immune cell and mutation counts in the DNA damage response (DDR) pathway. In the immunotherapy cohort (N = 350), ZFHX3 mutations were an independent predictive biomarker for NSCLC patients receiving ICI treatment. Significant differences were observed between ZFHX3-mutant (ZFHX3-MT) and ZFHX3-wild type (ZFHX3-WT) patients regarding the overall survival (OS) time (P < 0.001, HR = 0.26, 95% Cl 0.17-0.41). ZFHX3-MT is significantly associated with higher tumor mutation burden (TMB) and neoantigen load (NAL), and ZFHX3-MT positively correlates with known immunotherapy response biomarkers, including T-cell infiltration, immune-related gene expression, and mutation counts in the DDR pathway in NSCLC. ZFHX3-MT is closely related to longer OS in NSCLC patients treated with ICIs, suggesting that ZFHX3 mutations be used as a novel predictive marker in guiding NSCLC ICI treatment.

学科与关键词

关键词
Non-small cell lung cancerZFHX3Immune checkpoint inhibitorBiomarker
相关
加载中…
  • ZFHX4 mutation as a novel predictive biomarker for immune checkpoint blockade in non-small cell lung cancer.
    Shen, Peng; Zeng, Di; Lin, Zhenzi; Lin, Pei; Luo, Mingyang; Zhao, Lele; Chai, Huizi; Huang, Lingli; Xiao, MingzheAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.
  • TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
    Lin, Anqi; Zhang, Hongman; Meng, Hui; Deng, Ze; Gu, Tianqi; Luo, Peng*; Zhang, Jian*Frontiers in Immunology, 2021, 12: 667875.被引 8
  • MGA Mutation as a Novel Biomarker for Immune Checkpoint Therapies in Non-Squamous Non-Small Cell Lung Cancer
    Sun, Lei; Li, Man; Deng, Ling; Niu, Yuchun; Tang, Yichun; Wang, Yu*; Guo, Linlang*Frontiers in Pharmacology, 2021, 12: 625593.被引 5
查看全部 →

发表信息

论文状态
公开发表
期刊
Cancer Immunology, Immunotherapy
发表日期
2021-01
卷期
第 70 卷, 第 1 期
页码
137-151
DOI
10.1007/s00262-020-02668-8
语言
ENGLISH
期刊收录
NSL
期刊等级
2区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81572244, 81602631, 81672267, 81772458, 81871859, 81972809]; Natural Science Foundation of Guangdong Province (key) [2015A030311028]; Clinical Research Initiative Project of Southern Medical University [LC2016ZD029, LC2019ZD016]; Major Basic Research Projects and Major Applied Research Projects of Educational Commission of Guangdong Province [2017KZDXM015]

作者

  • Z

    Zhang, Jiexia (第一作者)

  • Z

    Zhou, Ningning

    sun yat sen univ

查看全部 10 位作者收起作者
  • L

    Lin, Anqi

    southern med univ

  • L

    Luo, Peng

    southern med univ

  • C

    Chen, Xin

    southern med univ

  • D

    Deng, Huojin

    southern med univ

  • K

    Kang, Shijun

    southern med univ

  • G

    Guo, Linlang (通讯)

    southern med univ

  • Z

    Zhu, Weiliang (通讯)

    southern med univ

  • Z

    Zhang, Jian

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417